ArticleTherapeutic advances in medical oncology2026

Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancer.

Paul Cottu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.